The deal includes a non-tradeable CVR that pays $1.00/sh for each of three contingencies (i.e. $3.00/sh maximum). The nominal deal value (excluding the CVR) is $487M.
AKUS is pursuing gene therapy for hearing conditions. The buyout price is 26% below AKUS’s 2020 IPO price of $17.00 (#msg-156532797).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”